Acelyrin (SLRN) News Today $4.43 -0.29 (-6.14%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period UCB gets FDA approval for Bimzelx for hidradenitis suppurativaNovember 20 at 6:16 PM | msn.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Acelyrin, Inc. (SLRN) and Encourages Long-Term SLRN Investors to Contact the FirmNovember 19 at 11:00 PM | markets.businessinsider.comHC Wainwright Increases Earnings Estimates for AcelyrinNovember 18 at 1:30 AM | americanbankingnews.comFY2024 EPS Estimates for Acelyrin Increased by HC WainwrightAcelyrin, Inc. (NASDAQ:SLRN - Free Report) - Research analysts at HC Wainwright raised their FY2024 EPS estimates for Acelyrin in a report released on Thursday, November 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($2.43) for the year, up froNovember 18 at 1:30 AM | marketbeat.comVikram Purohit’s Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock MovementNovember 15, 2024 | markets.businessinsider.comStrategic Shifts and Promising Developments Drive ACELYRIN’s Potential Share DoublingNovember 14, 2024 | markets.businessinsider.comAcelyrin’s Phase 3 Trial Progress and Uncertainties Lead to Hold RatingNovember 14, 2024 | markets.businessinsider.comACELYRIN, INC. Receives Buy Rating from Tyler Van Buren Due to Clinical Progress and Strategic AdvancementsNovember 14, 2024 | markets.businessinsider.comAcelyrin, Inc. (SLRN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 13, 2024 | globenewswire.comEarnings Preview: AcelyrinNovember 13, 2024 | benzinga.comAcelyrin (SLRN) Scheduled to Post Earnings on WednesdayAcelyrin (NASDAQ:SLRN) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024November 6, 2024 | globenewswire.comAcelyrin, Inc. (NASDAQ:SLRN) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to thOctober 28, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Short Interest Down 19.2% in OctoberAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 5,160,000 shares, a decrease of 19.2% from the September 30th total of 6,390,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is presently 5.1 days. Approximately 8.0% of the shares of the stock are sold short.October 27, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Stock Price Down 6.9% - Here's What HappenedAcelyrin (NASDAQ:SLRN) Stock Price Down 6.9% - What's Next?October 18, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading Up 4.8% on Analyst UpgradeAcelyrin (NASDAQ:SLRN) Stock Price Up 4.8% After Analyst UpgradeOctober 17, 2024 | marketbeat.comACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseOctober 16, 2024 | markets.businessinsider.comWells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00Wells Fargo & Company lifted their target price on Acelyrin from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday.October 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Stock Price Down 2.4% - What's Next?Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4% - Time to Sell?October 11, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Up 5.9% - Time to Buy?Acelyrin (NASDAQ:SLRN) Trading 5.9% Higher - Here's What HappenedOctober 10, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 83.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,542 shares of the company's stock after selling 185,October 6, 2024 | marketbeat.comMillennium Management LLC Boosts Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)Millennium Management LLC grew its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 15.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,642,056 shares of the company's stock after buying an additional 628,528October 5, 2024 | marketbeat.comRenaissance Technologies LLC Raises Position in Acelyrin, Inc. (NASDAQ:SLRN)Renaissance Technologies LLC lifted its stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 218.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 397,618 shares of the company's stock after purchasing aOctober 4, 2024 | marketbeat.com160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLCSusquehanna Fundamental Investments LLC bought a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 160,167 shares of the company's stock, valued at apOctober 3, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Rating of "Moderate Buy" by AnalystsAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating onOctober 3, 2024 | marketbeat.comAlmitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN)Almitas Capital LLC bought a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 376,116 shares of the company's stock, valued at approximatelySeptember 29, 2024 | marketbeat.comShort Interest in Acelyrin, Inc. (NASDAQ:SLRN) Drops By 15.4%Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 6,090,000 shares, a drop of 15.4% from the August 31st total of 7,200,000 shares. Approximately 9.5% of the shares of the company are sold short. Based on an average daily volume of 1,190,000 shares, the days-to-cover ratio is presently 5.1 days.September 28, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 5.4% Acelyrin (NASDAQ:SLRN) Trading Down 5.4%September 23, 2024 | marketbeat.comGenSight Biologics S.A. (G49N.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024September 19, 2024 | globenewswire.comAcadian Asset Management LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)Acadian Asset Management LLC bought a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 134,184 shares of the company's stock, valued at approximately $590,000September 18, 2024 | marketbeat.comLos Angeles Capital Management LLC Invests $693,000 in Acelyrin, Inc. (NASDAQ:SLRN)Los Angeles Capital Management LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 157,093 shares of the company's stock, valued at approximately $6September 14, 2024 | marketbeat.comSignificant Acquisition by T. Rowe Price Investment Management in Acelyrin IncSeptember 12, 2024 | uk.finance.yahoo.comAcelyrin, Inc. (NASDAQ:SLRN) Given Consensus Recommendation of "Moderate Buy" by AnalystsAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buSeptember 8, 2024 | marketbeat.comACELYRIN, INC. to Participate in Upcoming Investor ConferencesAugust 22, 2024 | globenewswire.comACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash RunwayAugust 20, 2024 | markets.businessinsider.comAcelyrin (NASDAQ:SLRN) PT Lowered to $6.00 at Morgan StanleyMorgan Stanley decreased their price objective on Acelyrin from $13.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Monday.August 19, 2024 | marketbeat.comHC Wainwright & Co. Downgrades Acelyrin (SLRN)August 16, 2024 | msn.comAcelyrin Shares Slide on Layoffs, Portfolio RefocusAugust 15, 2024 | marketwatch.comPiper Sandler Keeps Their Buy Rating on ACELYRIN, INC. (SLRN)August 15, 2024 | markets.businessinsider.comACELYRIN, INC. Maintains Hold Rating Amidst Mixed Clinical Results and Competitive Market ChallengesAugust 15, 2024 | markets.businessinsider.comAcelyrin Cuts Workforce, Deprioritizes Former Lead Drug IzokibepAugust 15, 2024 | msn.comAcelyrin (NASDAQ:SLRN) Posts Earnings Results, Misses Expectations By $0.08 EPSAcelyrin (NASDAQ:SLRN - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same period last year, the firm earned ($0.56) EPS.August 14, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to theAugust 14, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) PT Lowered to $20.00 at Piper SandlerPiper Sandler lowered their target price on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday.August 14, 2024 | marketbeat.comAcelyrin, Inc. (SLRN) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comAcelyrin, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 13, 2024 | seekingalpha.comInvestors reduced allocations to stocks, moved to cash in August, BofA survey showsAugust 13, 2024 | ca.finance.yahoo.comAcelyrin to Reduce Workforce by One-Third as Portfolio's Priorities ShiftAugust 13, 2024 | marketwatch.com Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin SLRN Media Mentions By Week SLRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼1.080.46▲Average Medical News Sentiment SLRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼133▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HRMY News EVO News RXRX News TARS News IRON News GLPG News XNCR News IMCR News NRIX News KNSA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRN Stock Alerts